Scarica l'app Stockscreener
60.27
1.43%
-0.875
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$61.15
Aprire:
$60.96
Volume 24 ore:
719.51K
Relative Volume:
0.73
Capitalizzazione di mercato:
$2.04B
Reddito:
$55.63M
Utile/perdita netta:
$-158.10M
Rapporto P/E:
-7.1578
EPS:
-8.4202
Flusso di cassa netto:
$-203.94M
1 W Prestazione:
+7.18%
1M Prestazione:
-14.66%
6M Prestazione:
+22.60%
1 anno Prestazione:
+551.57%
Intervallo 1D:
$59.09
$61.15
Intervallo di 1 settimana:
$55.31
$61.51
Portata 52W:
$8.27
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
60.27 | 2.07B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
NKTR: 5,538 RSUs registered for resale via Morgan Stanley (NKTR) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Nektar Therapeutics: Shareholders Board Members Managers and Company Profile | US6402683063 - marketscreener.com
NKTR News | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics (NKTR) Slips 1.5% Amid Consolidation Near Key Support LevelsFloat Adjusted Cap - newsline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program? - simplywall.st
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility - Yahoo Finance
Inventory turnover of Nektar Therapeutics – XETR:ITH0 - TradingView
Nektar Therapeutics 8-K SEC Filing: Company Details, Common Stock, and NASDAQ Listing (June 2026) - Minichart
Diluted net income available to common stockholders of Nektar Therapeutics – XETR:ITH0 - TradingView
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Pullback - simplywall.st
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock - Insider Monkey
Nektar Therapeutics (NKTR) holders back plan share boost and auditor at 2026 meeting - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
NKTR: All proposals passed; immunology pipeline advances with REZPEG entering phase III trials - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - The National Law Review
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Drug developers outpace Nasdaq Bio, rezpeg data sends up Nektar - BioWorld News
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - The AI Journal
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com
Nektar Therapeutics to webcast at 2026 Jefferies Global Healthcare Conference on June 3 - Pluang
How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan
Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool
Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI
Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer |
May 19 '26 |
Sale |
65.51 |
199 |
13,036 |
20,975 |
| ROBIN HOWARD W | President & CEO |
May 19 '26 |
Sale |
65.51 |
444 |
29,086 |
75,045 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):